Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658478 | 0.87 | CCR5 (0.58) | CCR5 | |
| SCHEMBL19652134 | 0.86 | CCR5 (0.52) | CCR5SIGMAR1KMT2AMEN1HTT | |
| SCHEMBL28003062 | 0.85 | ACHE (0.58) | SIGMAR1KMT2AMEN1ATMALDH1A1 | |
| SCHEMBL19658384 | 0.85 | ATM (0.55) | SIGMAR1KMT2AMEN1HTTATM | |
| SCHEMBL19658841 | 0.84 | TACR2 (0.55) | CCR5SIGMAR1KMT2AMEN1ATM | |
| SCHEMBL19658471 | 0.81 | NOS3 (0.48) | CCR5SIGMAR1ALDH1A1LMNADRD2 | |
| SCHEMBL9030647 | 0.81 | SIGMAR1 (0.67) | SIGMAR1DRD2 | |
| SCHEMBL1921304 | 0.79 | SIGMAR1 (0.53) | CCR5SIGMAR1KMT2AMEN1HTT | |
| SCHEMBL19658394 | 0.78 | ATM (0.53) | SIGMAR1KMT2AMEN1HTTATM | |
| SCHEMBL28003341 | 0.77 | CCR3 (0.48) | CCR5SIGMAR1ALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CCR5 1178/4885SIGMAR1 1530/4885KMT2A 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.